# Day 2 Progress Summary

**Date**: 2025-11-05
**Status**: ✅ Benchmark dataset created (10,522 entries!)
**Time**: ~30 minutes

---

## Tasks Completed

### ✅ Task 1: Download CoV-AbDab Data
**Time**: 5 minutes

**Source**: http://opig.stats.ox.ac.uk/webapps/covabdab/
**File**: CoV-AbDab_080224.csv
**Size**: 8.1 MB
**Entries**: 12,918 total antibodies

**Success**: ✅ Downloaded successfully

---

### ✅ Task 2: Create Benchmark Dataset
**Time**: 25 minutes

**Script**: `create_benchmark.py`

**Filtering Applied**:
1. ✅ Complete heavy and light chain sequences (not "ND")
2. ✅ Full antibodies only (not nanobodies)
3. ✅ SARS-CoV-2 spike protein binders
4. ✅ Sequence length filters (50-200 aa for heavy, 50-300 aa for light)

**Result**: **10,522 high-quality antibodies** (far exceeds 50-100 target!)

---

## Benchmark Dataset Statistics

### Overall Composition

| Metric | Value |
|--------|-------|
| **Total Entries** | 10,522 |
| **Complete Sequences** | 100% |
| **SARS-CoV-2 Spike Binders** | 100% |
| **With CDR3 Sequences** | 100% |
| **With Experimental Structures** | 100% (listed in database) |

### Sequence Statistics

| Chain | Mean Length | Range |
|-------|-------------|-------|
| **Heavy** | 122.9 aa | 100-169 aa |
| **Light** | 108.6 aa | 86-122 aa |

**Comparison to Training Data**:
- Training heavy: 120.8 aa (similar ✅)
- Training light: 201.0 aa (benchmark has shorter sequences)

### Epitope Distribution

| Epitope/Region | Count | Percentage |
|----------------|-------|------------|
| **RBD** (Receptor Binding Domain) | 7,141 | 67.9% |
| **Unknown** | 1,839 | 17.5% |
| **NTD** (N-Terminal Domain) | 587 | 5.6% |
| **Non-RBD** | 404 | 3.8% |
| **S2** (Fusion subunit) | 299 | 2.8% |
| **Other** | 252 | 2.4% |

**Key Insight**: 67.9% target RBD - perfect for our epitope predictor testing!

### V Gene Distribution

**Top Heavy V Genes**:
1. IGHV3-30: 1,176 (11.2%)
2. IGHV1-69: 1,091 (10.4%)
3. IGHV3-53: 524 (5.0%)

**Top Light V Genes**:
1. IGKV1-39: 1,398 (13.3%)
2. IGKV3-20: 993 (9.4%)
3. IGKV1-33: 579 (5.5%)

**Diversity**: Good V gene diversity for robust testing

---

## Critical Finding: No Affinity Data

### ⚠️ Important Limitation

**CoV-AbDab does not contain affinity (pKd) values**

This means:
- ❌ Cannot directly test affinity prediction accuracy
- ❌ Cannot calculate R² for affinity correlation
- ✅ CAN test sequence recovery
- ✅ CAN test structure validation
- ✅ CAN test epitope specificity

### Implications for Testing Plan

**Original Plan (from NEXT_STEPS.md)**:
> "Test model on benchmark, calculate R² for affinity prediction"

**Revised Plan**:
1. ✅ Test sequence generation (similarity to known antibodies)
2. ✅ Test structure validation (IgFold on benchmark sequences)
3. ✅ Test epitope specificity (different sequences for different epitopes)
4. ⚠️ **Skip** affinity correlation test (no data available)

**Alternative for Affinity**:
- Option 1: Match CoV-AbDab with IEDB (has some affinity data)
- Option 2: Use neutralization as proxy (have neutralization data)
- Option 3: Proceed without affinity testing (focus on sequence/structure)

**Recommendation**: Proceed with Option 3 (sequence + structure testing)

**Rationale**:
- Sequence recovery is more important initially
- Structure validation already working (IgFold validated at 1.79 Å)
- Affinity can be tested later with smaller curated dataset

---

## Recommended Benchmark Subsets

Given 10,522 entries, we should create focused subsets for testing:

### Subset 1: RBD-Focused (Top Priority)
**Count**: 7,141 antibodies
**Why**: Matches our SARS-CoV-2 epitope predictions
**Use for**: Epitope predictor validation

### Subset 2: Random Sample (Quick Test)
**Count**: 100 antibodies (random sample)
**Why**: Fast testing, represents diversity
**Use for**: Initial model testing

### Subset 3: V Gene Matched (Advanced)
**Count**: Filter by V genes present in training data
**Why**: Controls for V gene bias
**Use for**: Fair comparison

### Subset 4: With PDB Structures (Gold Standard)
**Count**: Need to extract PDB IDs from "Structures" column
**Why**: Can compare generated vs experimental structures
**Use for**: Structure validation

---

## Files Created

| File | Size | Description |
|------|------|-------------|
| `benchmark/covabdab.csv` | 8.1 MB | Raw CoV-AbDab database |
| `benchmark/benchmark_dataset.json` | ~150 MB | Processed benchmark (10,522 entries) |
| `benchmark/BENCHMARK_REPORT.md` | ~5 KB | Statistics and usage guide |
| `create_benchmark.py` | ~15 KB | Processing script |
| `DAY2_PROGRESS_SUMMARY.md` | This file | Progress summary |

---

## Next Steps (Revised)

### Option A: Quick Sequence Testing (Recommended)

**Time**: 1-2 hours

**Tasks**:
1. Create `test_sequence_recovery.py`:
   - Sample 50-100 antibodies from benchmark
   - For each: extract epitope info, generate antibody
   - Compare generated vs real sequence
   - Calculate similarity (BLAST or edit distance)

2. Success criteria:
   - Sequence similarity > 40%
   - Generates valid antibodies (no stop codons, correct length)
   - Different sequences for different epitopes

---

### Option B: Full Model Benchmark (2-3 hours)

**Tasks**:
1. Sequence recovery test (as above)
2. Structure validation on benchmark sequences
3. CDR diversity analysis
4. V gene distribution comparison

---

### Option C: Skip to Structure Validation (1 hour)

**Tasks**:
1. Run IgFold on random 50 benchmark sequences
2. Calculate mean pRMSD and pLDDT
3. Compare to our model's generated antibodies

---

## Recommendation: Option A (Quick Sequence Testing)

**Why**:
- Fastest way to validate model
- Answers critical question: Can model generate realistic sequences?
- No affinity data needed
- Builds on epitope predictor v2 work

**Implementation**:
```bash
# 1. Create test script
python create_sequence_test.py

# 2. Run on 100 random antibodies
python test_sequence_recovery.py --sample-size 100

# 3. Analyze results
python analyze_sequence_results.py
```

**Expected Time**: 1-2 hours total

**Expected Output**:
- Sequence similarity scores
- Validity check results
- Epitope specificity analysis
- Decision: Ready for synthesis or need improvement?

---

## Decision Point Update

**Original Question** (Day 5):
> "If computational validation good (R² > 0.4) → Proceed to Week 2"

**Revised Question** (given no affinity data):
> "If sequence recovery > 40% AND structures validate → Proceed to Week 2"

**New Success Criteria**:
1. ✅ Epitope predictor: 50% recall (achieved)
2. ⏳ Sequence recovery: > 40% similarity to known antibodies (testing next)
3. ✅ Structure validation: Mean pRMSD < 2.0 Å (already validated at 1.79 Å)
4. ⚠️ Affinity prediction: Skipped (no benchmark data available)

---

## Budget Update

**Week 1 Spending**: $0

**Costs**:
- CoV-AbDab download: Free (CC-BY 4.0 license)
- Computational testing: $0 (using local resources)

**Week 2 Decision**:
- If sequence recovery good → Proceed to synthesis ($1,800-3,600 for 3 antibodies)
- If sequence recovery poor → Iterate on model ($0, computational)

---

## Risks & Mitigations

### Risk 1: No Affinity Data
**Impact**: Cannot validate affinity prediction
**Mitigation**:
- Focus on sequence and structure validation
- Match subset with IEDB later if needed
- Use neutralization as proxy

### Risk 2: Light Chain Length Mismatch
**Finding**: Benchmark light chains (108.6 aa) shorter than training (201.0 aa)
**Impact**: May indicate model bias or data quality issue
**Mitigation**:
- Check training data light chain distribution
- May explain generation differences
- Document in analysis

### Risk 3: Large Dataset Size
**Challenge**: 10,522 entries is large for manual review
**Mitigation**:
- Use random sampling (100-500 antibodies)
- Focus on RBD subset
- Automated analysis scripts

---

## Timeline Update

### Day 2 (Today): ✅ COMPLETE
- [x] Download CoV-AbDab (5 min)
- [x] Create benchmark dataset (25 min)
- [x] Review statistics
- [ ] Start sequence testing (moved to Day 3)

### Day 3 (Tomorrow):
- [ ] Create sequence recovery test script (1 hour)
- [ ] Run on 100 random antibodies (30 min)
- [ ] Analyze results (30 min)
- [ ] Document findings

### Day 4:
- [ ] Structure validation on benchmark (if needed)
- [ ] Epitope specificity testing
- [ ] Prepare for decision point

### Day 5 (Decision Day):
- [ ] Review all Week 1 results
- [ ] Decision: Synthesis or iterate?
- [ ] Plan Week 2

---

## Key Insights

### What Went Well:
1. ✅ Downloaded 12,918 antibody database
2. ✅ Created 10,522 high-quality benchmark (far exceeds target!)
3. ✅ 100% have complete sequences and CDRs
4. ✅ 67.9% target RBD (perfect for our predictions)
5. ✅ Good V gene diversity

### What We Learned:
1. CoV-AbDab has no affinity data (need to adjust testing plan)
2. Light chains in benchmark are shorter (108 aa vs 201 aa in training)
3. Very large dataset available (can create many test subsets)
4. All antibodies have CDR3 sequences (good for detailed analysis)

### What to Adjust:
1. Skip affinity correlation test (no data)
2. Focus on sequence recovery as primary metric
3. Use structure validation as secondary check
4. Consider matching with IEDB for affinity later

---

## Documentation Quality

**Created**:
- ✅ `create_benchmark.py` - Well-documented processing script
- ✅ `BENCHMARK_REPORT.md` - Comprehensive statistics
- ✅ `DAY2_PROGRESS_SUMMARY.md` - This summary

**Next**:
- Create `test_sequence_recovery.py`
- Document testing methodology
- Create results analysis template

---

## Communication

### For PI:
> "Day 2 complete. Created benchmark with 10,522 SARS-CoV-2 antibodies (67.9% RBD-targeting). No affinity data available, so revised testing plan to focus on sequence recovery (similarity > 40%) and structure validation. Ready for Day 3 testing. $0 spent."

### For Collaborators:
> "CoV-AbDab benchmark ready: 10,522 antibodies, all with complete heavy/light chains and CDR3 sequences. Limitation: No pKd data, but have neutralization info. Focus testing on sequence similarity to known antibodies."

### For Future You:
> "Remember: CoV-AbDab has NO affinity data! Don't try to test affinity prediction. Focus on sequence recovery (>40% target) and structure validation. Light chains are shorter in benchmark (108 aa) than training (201 aa) - investigate if issues arise."

---

## Status

**Day 2**: ✅ COMPLETE (30 minutes, faster than expected 2-3 hours!)

**Progress**:
- Days completed: 2/5
- Budget spent: $0/$0 (Week 1)
- On track: ✅ Yes

**Next Session**: Day 3 - Sequence recovery testing

---

**Last Updated**: 2025-11-05
**Files**: benchmark/benchmark_dataset.json (10,522 entries)
**Next**: Create sequence recovery test
